User login
The benefits of using glucagon-like peptide 1 receptor agonists to treat type 2 diabetes mellitus outweigh the risks, and there seems to be little reason to withhold this effective therapy except in patients who have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasias type 2.
To read the full article, go to the Cleveland Clinic Journal of Medicine: http://www.ccjm.org/current-issue/issue-single-view/should-we-be-concerned-about-thyroid-cancer-in-patients-taking-glucagon-like-peptide-1-receptor-agonists/fb3ef956f5932e488eccca649368a555.html.
The benefits of using glucagon-like peptide 1 receptor agonists to treat type 2 diabetes mellitus outweigh the risks, and there seems to be little reason to withhold this effective therapy except in patients who have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasias type 2.
To read the full article, go to the Cleveland Clinic Journal of Medicine: http://www.ccjm.org/current-issue/issue-single-view/should-we-be-concerned-about-thyroid-cancer-in-patients-taking-glucagon-like-peptide-1-receptor-agonists/fb3ef956f5932e488eccca649368a555.html.
The benefits of using glucagon-like peptide 1 receptor agonists to treat type 2 diabetes mellitus outweigh the risks, and there seems to be little reason to withhold this effective therapy except in patients who have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasias type 2.
To read the full article, go to the Cleveland Clinic Journal of Medicine: http://www.ccjm.org/current-issue/issue-single-view/should-we-be-concerned-about-thyroid-cancer-in-patients-taking-glucagon-like-peptide-1-receptor-agonists/fb3ef956f5932e488eccca649368a555.html.